Open database of authors and journals


Crizanlizumab 5.0 Mg/Kg Exhibits a Favorable Safety Profile in Patients with Sickle Cell Disease: Pooled Data from Two Phase II Studies

Blood, 2019, 134, 991-991

Citation of paper, Crizanlizumab 5.0 Mg/Kg Exhibits a Favorable Safety Profile in Patients with Sickle Cell Disease: Pooled Data from Two Phase II Studies

Authors Citing This Paper

AuthorCiting PapersAuthor's PapersAuthor's CitationsAuthor's IF
Jin Han1781,7073

Journals Citing This Paper

JournalCiting PapersJournal's IFJournal's Star
Pharmacotherapy15.8★★
American Journal of Physiology - Lung Cellular and Molecular Physiology15.8★★

Similar Articles

Quick Tips
This is an overview of where and by who this paper has been cited.
Help Us
Non-profit projects normally ask for donations. We don't. We will survive one way or another. If you wish to help us, please spread the word to let more people use this service.

It is delightful to see our efforts are useful to a broad range of researchers.
EXALY
Profiles
Fields
Search Engines
Tools